Evidence map›Paper›PMID 24067444›Full record

ReviewVirulence2013

Can biowarfare agents be defeated with light?

Fatma Vatansever, Cleber Ferraresi, Marcelo Victor Pires de Sousa, Rui Yin, Ardeshir Rineh, Sulbha K Sharma, Michael R Hamblin

Open access · goldAbstract readReview
In one paragraph

Review in Virulence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Use of Clinical UV Chamber to Disinfect Dental Impressions: A Comparative Study.Journal of clinical and diagnostic research : JCDR · 2015
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 5 countries.

Fatma VatanseverWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; Harvard Medical School; Department of Dermatology; Boston, MA USA.
Cleber FerraresiWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; Laboratory of Electro-thermo-phototherapy; Department of Physical Therapy; Federal University of São Carlos; São Paulo, Brazil; Post-Graduation Program in Biotechnology; Federal University of São Carlos; São Paulo, Brazil; Optics Group; Physics Institute of Sao Carlos; University of São Paulo; São Carlos, Brazil.
Marcelo Victor Pires de SousaWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; Laboratory of Radiation Dosimetry and Medical Physics; Institute of Physics, São Paulo University, São Paulo, Brazil.
Rui YinWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; Harvard Medical School; Department of Dermatology; Boston, MA USA; Department of Dermatology; Southwest Hospital; Third Military Medical University; Chongqing, PR China.
Ardeshir RinehWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; School of Chemistry; University of Wollongong; Wollongong, NSW Australia.
Sulbha K SharmaWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; Raja Ramanna Centre for Advanced Technology; Indore, India.
Michael R HamblinWellman Center for Photomedicine; Massachusetts General Hospital; Boston MA USA; Harvard Medical School; Department of Dermatology; Boston, MA USA; Harvard-MIT Division of Health Sciences and Technology; Cambridge, MA USA.
Massachusetts General Hospital · USRaja Ramanna Centre for Advanced Technology · INSouthwest General Health Center · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
NIAID NIH HHS R01 AI050875NIAID NIH HHS R01AI050875
6 · The paper itself

Abstract

Biological warfare and bioterrorism is an unpleasant fact of 21st century life. Highly infectious and profoundly virulent diseases may be caused in combat personnel or in civilian populations by the appropriate dissemination of viruses, bacteria, spores, fungi, or toxins. Dissemination may be airborne, waterborne, or by contamination of food or surfaces. Countermeasures may be directed toward destroying or neutralizing the agents outside the body before infection has taken place, by destroying the agents once they have entered the body before the disease has fully developed, or by immunizing susceptible populations against the effects. A range of light-based technologies may have a role to play in biodefense countermeasures. Germicidal UV (UVC) is exceptionally active in destroying a wide range of viruses and microbial cells, and recent data suggests that UVC has high selectivity over host mammalian cells and tissues. Two UVA mediated approaches may also have roles to play; one where UVA is combined with titanium dioxide nanoparticles in a process called photocatalysis, and a second where UVA is combined with psoralens (PUVA) to produce "killed but metabolically active" microbial cells that may be particularly suitable for vaccines. Many microbial cells are surprisingly sensitive to blue light alone, and blue light can effectively destroy bacteria, fungi, and Bacillus spores and can treat wound infections. The combination of photosensitizing dyes such as porphyrins or phenothiaziniums and red light is called photodynamic therapy (PDT) or photoinactivation, and this approach cannot only kill bacteria, spores, and fungi, but also inactivate viruses and toxins. Many reports have highlighted the ability of PDT to treat infections and stimulate the host immune system. Finally pulsed (femtosecond) high power lasers have been used to inactivate pathogens with some degree of selectivity. We have pointed to some of the ways light-based technology may be used to defeat biological warfare in the future.

Indexed as

Biological Warfare AgentsLightUltraviolet RaysBacteriaFungiHumansMicrobial ViabilityPhotochemotherapyPhotosensitizing AgentsToxins, BiologicalVirusesBiological Warfare AgentsPhotosensitizing AgentsToxins, Biologicalbioterrorismbiowarfareblue light inactivationgermicidal ultravioletmicrobial cellsphotocatalysisphotocatalytic inactivationphotodynamic therapyphoto inactivationpsoralestitanium dioxideultraviolet lightUV dosimeters

Identifiers

PMID24067444
PMCPMC3925713
OpenAlexW2171944637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.